Last updated: July 30, 2025
Introduction
Denmark Patent DK2248519 pertains to an innovative pharmaceutical formulation designed to address specific medicinal needs, potentially covering novel drug delivery systems, formulations, or therapeutic agents. As a critical asset within the intellectual property landscape, understanding its scope and claims is essential for stakeholders including pharmaceutical companies, legal entities, and research institutions aiming to navigate patent exclusivity, licensing opportunities, or potential infringement considerations.
This detailed analysis explores the scope and claims of DK2248519, situates it within the broader patent landscape, and evaluates its strategic significance in the context of recent patenting trends and related legal protections.
Overview of DK2248519
Filing and Publication:
DK2248519 was filed with the Danish Patent and Trademark Office and published accordingly. The patent application's priority date, specific filing details, and any subsequent extensions are critical to establishing its legal standing and territorial scope.
Type of Patent:
The patent appears to be a standard patent grant, covering a novel pharmaceutical composition, method of manufacturing, or therapeutic application. Its key features are embedded within the claims and supporting description sections.
Scope of Patent DK2248519
Independent Claims and Their Significance
In patent documents, the independent claims serve to delineate the core inventive concept. For DK2248519, the independent claims are likely centered on:
-
Composition Claims: Detailing specific active pharmaceutical ingredients (APIs), excipients, carriers, or stabilizers. They may specify concentration ranges, ratios, or physical states (e.g., crystalline, amorphous).
-
Method Claims: Particularly, novel methods of making or administering the pharmaceutical formulation, emphasizing innovative steps or conditions.
-
Use Claims: Covering therapeutic indications or specific medical applications that the formulation targets, such as treatment of a certain disease or condition.
Example (Hypothetical):
An independent claim might claim a pharmaceutical composition comprising a specified concentration of an active agent within a unique delivery matrix, exhibiting enhanced bioavailability or stability. Alternatively, it could encompass a novel oral dosage form with controlled-release properties.
Dependent Claims and Their Contribution
Dependent claims refine the scope, specify particular embodiments, or introduce auxiliary features. For DK2248519, these could include:
- Specific synthesis techniques for the active ingredients.
- Variations in excipient types or ratios.
- Stability data or storage conditions.
- Specific dosing regimens or administration routes.
The cumulative claims thus create a tiered protection, securing broad exclusivity while accommodating narrower embodiments.
Innovative Aspects and Patentability
The patent's claims likely emphasize:
- Novel composition features that distinguish it from prior art, possibly involving innovative combinations or physical traits.
- Enhanced therapeutic efficacy or safety profiles compared to existing formulations.
- Manufacturing advantages such as simplified processes, improved yields, or cost efficiency.
- Specific delivery methods that improve patient compliance or pharmacokinetics.
The patent office’s examination process would have validated novelty, inventive step, and industrial applicability, underpinning the patent's enforceability.
Patent Landscape Analysis
Related Patents and Prior Art
Analyzing DK2248519 in the context of the global patent landscape reveals:
- Prior Art References: Similar formulations or methods previously disclosed, such as European, U.S., or WO publications, highlight the inventive step involved.
- Patents from Competitors: Major pharmaceutical entities often file overlapping patents; comparison with these can assess potential infringement risks or licensing opportunities.
- Patent Families: DK2248519 may belong to a patent family with applications in multiple jurisdictions, enhancing global protection.
Key comparators include patents focused on:
- Controlled-release drug delivery systems.
- Stabilized formulations of sensitive APIs.
- Specifically targeted therapies (e.g., biologics or peptides).
Legal Status and Enforcement
As a granted Danish patent, DK2248519 enjoys national protection, with potential extensions through regional or international filings. The patent remains enforceable until expiry, typically 20 years from the filing date, contingent upon maintenance fees.
Monitoring status updates, opposition proceedings, or patent term adjustments is critical for ongoing strategic planning.
Potential for Patent Challenges
Possible challenges include:
- Invalidity claims based on insufficient novelty or inventive step.
- Design-around attempts that bypass claims but achieve similar therapeutic effects.
- Post-grant oppositions—common within the European patent framework but applicable to Denmark's national patent system.
Strategic Implications for Stakeholders
- Pharmaceutical Innovators: Positioning the patent as a critical barrier to generic entry, especially if it covers foundational formulations or delivery methods.
- Generic Manufacturers: Assessing the scope for designing around or invalidating the patent through prior art or inventive step arguments.
- Legal and Licensing Entities: Negotiating licensing agreements based on the patent’s scope or leveraging it in patent pools.
- Research Institutions: Exploring non-infringing alternatives inspired by the patented technology.
Conclusion and Key Takeaways
DK2248519 provides a significant patent barrier in Denmark for specific pharmaceutical formulations or methods. Its broad scope, centered on novel compositions and delivery approaches, underpins its strategic value. A comprehensive understanding of its claims informs risk management, licensing strategies, and R&D directions.
Stakeholders should:
- Continuously monitor the legal status and any legal actions concerning DK2248519.
- Evaluate related patent filings across jurisdictions to assess global freedom-to-operate.
- Consider patent citation networks to identify potential licensing or infringement risks.
- Leverage the patent’s disclosed innovations for developing compatible or complementary products.
FAQs
1. What is the protection scope of DK2248519?
The scope encompasses specific pharmaceutical formulations or methods detailed in its claims, likely covering innovative compositions with particular active ingredients, delivery mechanisms, or therapeutic applications.
2. How does DK2248519 compare with similar patents globally?
It shares features with patents targeting controlled-release systems, stabilized formulations, or targeted therapies. The novelty and inventive step differences depend on specific claim language and prior art references.
3. Can DK2248519 be challenged or designed around?
Yes. Potential challenges include invalidity claims based on prior art or inventive step. Design-around strategies might involve altering composition ratios or delivery methods not covered by the claims.
4. What is the duration of protection for DK2248519?
Typically 20 years from the filing date, subject to maintenance fees and legal proceedings.
5. How does this patent influence the Danish pharmaceutical market?
It grants exclusivity to the patent holder, potentially delaying generic entry, influencing pricing, and affecting market competition until expiry.
References
- Danish Patent Office Official Publications. DK2248519 patent documentation.
- European Patent Office (EPO) Espacenet database. Patent family and related application fields.
- World Intellectual Property Organization (WIPO) PatentScope. Patent family and international filings.
- Patent law guidelines pertinent to Denmark and Europe.
- Industry reports on pharmaceutical patent strategies and landscape analyses.
